  |
Neonatal Drug Therapy Manual |
Cyclopentolate/Phenylephrine (Special Access Program)
Disclaimer: Official controlled document is the CHEO and Ottawa Hospital online copy. It is the responsibility of user to ensure that any paper copy version is the same as the online version before use.
Classification:
Anticholinergic, Mydriatic
Indications:
- To produce a mydriasis of the eye, prior to examination
Administration:
- Ophthalmic
- To minimize systemic absorption, apply finger pressure on the lacrimal sac for 1 - 2 minutes following instillations
Dosage:
- Instill 1 drop Q5 minutes x 3 doses at time ordered by MD
Side Effects:
- CVS: tachycardia, hypertension
- GI: feeding intolerance
- Local: transient stinging
- Ocular: elevated intraoccular pressure, photophobia
Reconstitution and Stability:
Notes:
Composition:
Each mL contains:
Cyclopentolate hydrochloride 2 mg
Phenylephrine hydrochloride 10 mg
Preserved with 0.01% benzalkonium chloride
References:
Oskan Derinoz, Hamdi C Emeksiz. Use of phystostigmine for cyclopentolate overdose in an infant. Pediatrics 2012; 130 e 703. August 20, 2012
Ayse Buyukcam, H. Tolga Celik, Korkmaz Ayse etal. Myoclonic seizure due to cyclopentolate eye drop in a pre term infant. The Turkish Journal of Pediatrics. 2012;54:419-20
Fitzgerald DA, Hanson RM, West C et al. Seizures associated with 1% cyclopentolate eye drops. J pediatric Child Health. 1990 April; 26 (2): 106-7
Systemic Toxicity of topical cyclopentolate eye drops in a child. Eye (2012) 26, 1391-1392: July 2012
The information contained on this website is provided for informational purposes only, as a guide to assist physicians, nurses and other healthcare providers in deciding on the appropriate care required for a particular patient. At all times, physicians, nurses and other healthcare providers must exercise their independent clinical judgment, based on their knowledge, training and experience, taking into account the specific facts and circumstances of each patient, when deciding on the appropriate course of investigation and/or treatment to recommend in a particular clinical situation.
CHEO has made every effort to ensure that the information contained on this website is as current and accurate as possible. However, changes can occur due to ongoing research and the constant influx of new information. Where possible, hospitals and healthcare practitioners should verify the information before acting on it.
Reliance on any information in this website is at the user's own risk. CHEO is not responsible or liable for any harm, loss or other consequences from the use or misuse of the information on this website.
